Regional brain atrophy in progressive supranuclear palsy and Lewy body disease

Annals of Neurology

Volumn 47, Issue 6, 2000, Pages 718-728

  Cordato, N J ^a   Halliday, G M ^a   Harding, A J ^a   Hely, M A ^b   Morris, J G L ^b  

^a NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE ASSOCIATION; FEMALE; HUMAN; LEWY BODY; MALE; NEUROPATHOLOGY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; VOLUMETRY;

AGED; AMYGDALA; ATROPHY; AUTOPSY; BASAL GANGLIA; BRAIN; CEREBRAL CORTEX; FEMALE; HIPPOCAMPUS; HUMANS; LEWY BODY DISEASE; MALE; PARKINSON DISEASE; PATIENT SELECTION; REGRESSION ANALYSIS; SUPRANUCLEAR PALSY, PROGRESSIVE; THALAMUS;

EID: 0034048193     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(200006)47:6<718::AID-ANA4>3.0.CO;2-J     Document Type: Article

References (65)

1. Schulz JB, Skalej M, Wedekind D, et al. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1999;45:65-74
2. Double KL, Halliday GM, McRitchie DA, et al. Regional brain atrophy in idiopathic Patkinson's disease and diffuse Lewy body disease. Dementia 1996;7:304-313
3. Laakso MP, Partanen K, Riekkinen P, et al. Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: an MRI study. Neurology 1996;46:678-681
4. Riekkinen P Jr, Kejonen K, Laakso MP, et al. Hippocampal atrophy is related to impaired memory, but not frontal functions in non-demented Parkinson's disease patients. Neuroreport 1998;9:1507-1511
5. Gelbe DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson's disease. Arch Neurol 1999;56:33-39
6. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124
7. Litvan I, Hauw JJ, Bartko JJ, et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol 1996;55:97-105
8. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82:239-259
9. Mirra SS, Heyman A, McKeel D, et al. The consortium to establish a registry tor Alzheimer's disease (CERAD). Part II. Standardization of the neuropathological assessment of Alzheimer's disease. Neurology 1991;41:479-486
10. Hughes CP, Berg L, Danziger WL, et al. A clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-572
11. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442
12. Hardman CD, Halliday GM, McRitchie DA, Morris JG. The subthalamic nucleus in Parkinson's disease and progressive supranuclear palsy. J Neuropathol Exp Neurol 1997;56:132-142
13. Daniel SE, de Bruin VM, Lees AJ. The clinical and pathological spectrum of Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy): a reappraisal. Brain 1995;118:759-770
14. Hauw J-J, Verny M, Delaere P, et al. Constant neurofibrillary changes in the neocortex in progressive supranuclear palsy: basic differences with Alzheimer's disease and aging. Neurosci Lett 1990;119:182-186
15. Verny M, Duyckaerts C, Agid Y, Hauw JJ. The significance of cortical pathology in progressive supranuclear palsy: clinicopathological data in 10 cases. Brain 1996;119:1123-1136
16. Halliday GM, McRitchie DA, Cartwright HR, et al. Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease. J Clin Neurosci 1996;3:52-60
17. Gómez-Tortosa E, Newell K, Irizarry MC, et al. Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology 1999;53:1284-1291
18. Kim H, Gearing M, Mirra S. Ubiquitin-positive CA2/3 neurites in hippocampus coexist with cortical Lewy bodies. Neurology 1995;45:1768-1770
19. Double KI., Halliday GM, Kril JJ, et al. Topography of brain atrophy during normal aging and Alzheimer's disease. Neurobiol Aging 1996;17:513-521
20. Halliday GM, McRitchie DA, Macdonald V, et al. Regional specificity of brain atrophy in Huntington's disease. Exp Neurol 1998;154:663-672
21. Dekaban AS. Changes in brain weights during the span of human life: relation of brain weights to body heights and weights. Ann Neurol 1978;4:345-356
22. Lippa CF, Johnson R, Smith TW. The medial temporal lobe in dementia with Lewy bodies: a comparative study with Alzheimer's disease. Ann Neurol 1998;43:102-106
23. Mann DM, Oliver R, Snowden JS. The topographic distribution of brain atrophy in Huntington's disease and progressive supranuclear palsy. Acta Neuropathol 1993;85:553-559
24. Yamauchi H, Fukuyama H, Nagahama Y, et al. Atrophy of the corpus callosum, cognitive impairment, and cortical hypometabolism in progressive supranuclear palsy. Ann Neurol 1997; 41:606-614
25. Hardman CD, Halliday GM, McRitchie DA, et al. Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata. Exp Neurol 1997;144:183-192
26. Hardman CD, Halliday GM. The internal globus pallidus is affected in progressive supranuclear palsy and Parkinson's disease. Exp Neurol 1999;158:135-142
27. Hardman CD, Halliday GM. The external globus pallidus in patients with Parkinson's disease and progressive supranuclear palsy. Mov Disord 1999;14:625-633
28. Halliday GM, Hardman CD, Cordato NJ, et al. A role for the substantia nigra pars reticulata in the gaze palsy of progressive supranuclear palsy. Brain 2000;123:724-732
29. Jernigan TL, Salmon DP, Butters N, Hesselink JR. Cerebral structure on MRI. Part II: specific changes in Alzheimer's and Huntington's diseases. Biol Psychiatry 1991;29:68-81
30. Aylward EH, Li Q, Stine OC, et al. Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology 1997;48:394-399
31. Soliveri P, Monza D, Paridi D, et al. Cognitive and magnetic resonance imaging aspects of corticobasal degeneration and progressive supranuclear palsy. Neurology 1999;53:502-507
32. Probst A, Luginbuhl M, Langui D, et al. Pathology of the striatum in progressive supranuclear palsy: abnormal tau proteins in astrocytes and cholinergic interneurons. Neurodegeneration 1993;2:183-193
33. Brandel J-P, Hirsch EC, Malessa S, et al. Differential vulnerability of cholinergic projections to the mediodorsal nucleus of the thalamus in senile dementia of Alzheimer type and progressive supranuclear palsy. Neuroscience 1991;41:25-31
34. Blin J, Baron JC, Dubois B, et al. Positron emission tomography study in progressive supranuclear palsy: brain hypometabolic pattern and clinicometabolic correlations. Arch Neurol 1990;47:747-752
35. D'Antona R, Baron JC, Samson Y, et al. Subcortical dementia. Frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy. Brain 1985; 108:785-799
36. Defebvre L, Lecouffe P, Destee A, et al. Tomographic measurements of regional cerebral blood flow in progressive supranuclear palsy and Parkinson's disease. Acta Neurol Scand 1995; 92:235-241
37. Foster NL, Gilman S, Berent S, et al. Cerebral hypometabolism in progressive supranuclear palsy with positron emission tomography. Ann Neurol 1988;24:399-406
38. Goffinet AM, De Voider AG, Gillain C, et al. Positron tomography demonstrates frontal lobe hypometabolism in progressive supranuclear palsy. Ann Neurol 1989;25:131-139
39. Johnson KA, Sperling RA, Holman BL, et al. Cerebral perfusion in progressive supranuclear palsy. J Nucl Med 1992;33: 704-709
40. Neary D, Snowden JS, Shields RA, et al. Single photon emission tomography using 99mTc-HM-PAO in the investigation of dementia. J Neurol Neurosurg Psychiatry 1987;50:1101-1109
41. Brooks DJ. PET studies on the early and differential diagnosis of Parkinson's disease. Neurology 1993;43:S6-S16
42. Churchyard A, Lees AJ. The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease. Neurology 1997;49:1570-1576
43. Hashimoto M, Kitagaki H, Imamura T, et al. Medial temporal and whole-brain atrophy in dementia with Lewy bodies: a volumetric MRI study. Neurology 1998;51:357-362
44. Harvey GT, Hughes J, McKeith IG, et al. Magnetic resonance imaging differences between dementia with Lewy bodies and Alzheimer's disease: a pilot study. Psychol Med 1999;29:181-187
45. Samuel W, Alford M, Hofstetter CR, Hansen L. Dementia with Lewy bodies versus pure Alzheimer disease: differences in cognition, neuropathology, cholinergic dysfunction, and synapse density. J Neuropathol Exp Neurol 1997;56:499-508
46. Kalra S, Bergeron C, Lang AE. Lewy body disease and dementia. Arch Intern Med 1996;156:487-493
47. Gnanalingham KK, Byrne EJ, Thornton A, et al. Motor and cognitive function of Lewy body dementia: comparison with Alzheimer's and Parkinson's diseases. J Neurol Neurosurg Psychiatry 1997;62:243-252
48. Braak H, Braak E, Yilmazer D, et al. Amygdala pathology in Parkinson's disease. Acta Neuropathol 1994;88:493-500
49. Braak H, Braak E, Yilmazer D, et al. Nigral and extranigral pathology in Parkinson's disease. J Neural Transm Suppl 1995; 46:15-31
50. Schmidt ML, Martin JA, Lee VM, Trojanowski JQ. Convergence of Lewy bodies and neurofibrillary tangles in amygdala neurons of Alzheimer's disease and Lewy body disorders. Acta Neuropathol 1996;91:475-481
51. Iseki E, Odawara T, Suzuki K, et al. A pathological study of Lewy bodies and senile changes in the amygdala in diffuse Lewy body disease. Neuropathology 1995;15:112-116
52. Rezaie P, Cairns NJ, Chadwick A, Lantos PL. Lewy bodies are located preferentially in limbic areas in diffuse Lewy body disease. Neurosci Lett 1996;212:111-114
53. Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 1988;38:1237-1244
54. Hawkes CH, Shephard BC, Daniel SE. Olfactory dysfunction in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62: 436-446
55. Mesholam RI, Moberg PJ, Mahr RN, Doty RL. Olfaction in neurodegenerative disease: a meta-analysis of olfactory functioning in Alzheimer's and Parkinson's diseases. Arch Neurol 1998; 55:84-90
56. Adolphs R, Tranel D, Damasio H, Damasio A. Impaired recognition of emotion in facial expressions following bilateral damage to the human amygdala. Nature 1994;372:669-672
57. Adolphs R, Tranel D, Damasio H, Damasio AR. Fear and the human amygdala. J Neurosci 1995;15:5879-5891
58. Cahill L, Babinsky R, Markowitsch HJ, McGaugh JL. The amygdala and emotional memory. Nature 1995;377:295-296
59. Morris JS, Frith CD, Perrett DI, et al. A differential neural response in the human amygdala to fearful and happy facial expressions. Nature 1996;383:812-815
60. Morris JS, Ohman A, Dolan RJ. Conscious and unconscious emotional learning in the human amygdala. Nature 1998;393: 467-470
61. Young AW, Aggleton JP, Hellawell DJ, et al. Face processing impairments after amygdalotomy. Brain 1995;118:15-24
62. Aggleton JP. The functional effects of amygdala lesions in humans: a comparison with findings from monkeys. In: Aggleton JP, ed. The amygdala: neurobiological aspects of emotion, memory, and mental dysfunction. New York: Wiley-Liss, 1992: 485-503
63. Sarter M, Markowitsch HJ. The amygdala's role in human mnemonic processing. Cortex 1985;21:7-24
64. DeWick HC, Hanley JR, Davies ADM, et al. Perception and memory for faces in Parkinson's disease. Neuropsychologia 1991;29:785-802
65. Jacobs DH, Shuren J, Bowers D, Heilman KM. Emotional facial imagery, perception, and expression in Parkinson's disease. Neurology 1995;45:1697-1702